| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Short-term investments | - | 29,789 | ||
| Cash and cash equivalents | 49,664 | 26,380 | ||
| Prepaid expenses | 141 | 1,922 | ||
| Other current assets | 2,100 | 2,404 | ||
| Total current assets | 51,905 | 60,495 | ||
| Property and equipment, net | - | 43 | ||
| Other non-current assets | 10 | 9 | ||
| Total assets | 51,915 | 60,547 | ||
| Accounts payable | 1,698 | 1,428 | ||
| Accrued expenses and other current liabilities | 2,533 | 4,184 | ||
| Total current liabilities | 4,231 | 5,612 | ||
| Non-current portion of deferred revenue | 35,000 | 35,000 | ||
| Total liabilities | 39,231 | 40,612 | ||
| Common shares, 0.14 par value 90,000,000 shares authorized as of september 30,2025, and december 31, 2024 26,305,295 shares issued and outstanding as of september 30,2025, and december 31, 2024 | 3,717 | 3,717 | ||
| Additional paid-in capital | 213,030 | 212,637 | ||
| Accumulated deficit | -194,279 | -187,091 | ||
| Accumulated other comprehensive loss | -9,784 | -9,328 | ||
| Total shareholders' equity | 12,684 | 19,935 | ||
| Total liabilities and shareholders' equity | 51,915 | 60,547 | ||
LAVA Therapeutics NV (LVTX)
LAVA Therapeutics NV (LVTX)